Matinas BioPharma Inc. (NYSE: MTNB) Starts Presentation at NobleCon16
Matinas BioPharma (NYSE: MTNB) is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, that was specifically designed to overcome the shortcomings seen from other agents in the omega-3 class. Matinas BioPharma is also developing MAT2203, an oral, encochleated formulation of amphotericin B, to treat serious invasive fungal infections. The drug is based on the company’s proprietary lipid nano-crystal (LNC) platform technology which can help solve complex challenges relating to…